Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

By G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, L. Gianni. Pharmacological Reviews, 2004

3,772 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/af8ed2ce06559c093aaa388d9e4ef208b6461bb1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. J. Januzzi
2. R. Russell
3. M. Volkova

Citations in the corpus

• Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems (2013, background): “Other doxorubicin actions include free radical generation which causes further DNA damage, inhibition of macromolecule production, DNA unwinding/separation and increase in alkylation.([18,19]) A recent study reported doxorubicin’s ability to intercalate with not only nuclear DNA, but also mitochondr”
• Microbial drug discovery: 80 years of progress (2009, background): “47 They are used to treat a wide range of cancers, including leukemias, lymphomas, and breast, uterine, ovarian and lung cancers.”
• Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab (2012, background): “Anthracyclines-induced cardiotoxicity is mainly mediated through the generation of reactive oxygen species and is accompanied by increased cardiomyocyte calcium overload and apoptosis, an irreversible process.(17) In contrast, human epidermal growth factor receptor 2-inhibitors disrupt myofibrillar ”
• Mitochondrial creatine kinase in human health and disease. (2006, positive): “The presence of intercellular iron and higher number of sites available for anthraquinone redox cycling likely favor in situ production of ROS and RNS [171,180,181], and anthracycline metabolites generated in the cells might also potentiate the toxic effects [169,170,178].”
• Immunogenic cell death and DAMPs in cancer therapy (2012, background): “These authors showed that a recombinant N-terminal fragment of CRT (39-272) is a potent inducer of activation and maturation of B cells and macrophages and can trigger Ig class switching in B cells without T cell help in vitro and in vivo72.”
• A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics (2012, neutral): “These molecules are among the most effective drugs available, inducing the greatest degree of cytotoxicity and used to treat the widest variety of tumor types including aggressive lymphoma, breast cancer, and myeloblastic leukemia (Minotti et al., 2004; Weiss, 1992).”
• Doxorubicin, DNA torsion, and chromatin dynamics (2013, neutral): “The quinone structure of doxorubicin can be oxidized to a semiquinone radical through addition of one electron, mediated by a number of NAD(P)H-oxidoreductases [5,34].”
• Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment (2011, background): “In fact, oxidant damage by doxorubicin in tumor cells is only seen at very high doxorubicin concentrations [26].”
• A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. (2014, background): “AlthoughDox plays a key role in the treatment ofmany neoplastic diseases, including human breast cancer [21], the clinical use of Dox has been greatly hampered by its dose-dependent cardiac toxicity (cardiomyopathy and congestive heart failure) [22].”
• A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death (2012, neutral): “However, anthracyclines suffer from dose-limiting side effects (Minotti et al , 2004; Vergely et al , 2007).”